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Objectives: thzs study azms to assess the zmpact of PTA on the quahty of life (QoL) of claudzcants and to analyse which 
patzents and whzch arterzal Ieszons derive the most benefit. 
Design: a prospective observational study 
Materials: one hundred and seventeen claudzcants undergozng PTA were studied, 35 patwnts had b~lateraI disease, 
whilst 82 had unilateral disease and underwent PTA to a solitary dzac lesion, sohtary superficzal femoral or a zhac leszon 
above a diseased superficzaI femoral artery zn 24, 39 and 19 cases, respectzvely. 
Methods: patients completed the Short Form 36 (SF36) and EuroQoI (EQ) QoL assessment instruments przor to and at 
1, 3, 6, and 12 months followmg intervention. The SF36 produces a QoL profile, whilst the EQ produces two QoL m&ces. 
Results: claudzcatzon has a deleterious effect on QoL, especially in patients w#h multz-segment dzsease. PTA results in 
an zmme&ate and Iastmg improvement in the QoL of claudwants. Unilateral claudwants undergoing PTA to a sohtary 
ihac lesmn demonstrate he most marked QoL benefits and 12 months post PTA report a QoL approaching &at of an 
age-matched populatzon. Patwnts w#h bilateral claudicatmn undergoing umlateral PTA and unilateral clau&cants 
undergoing PTA to a sohtary SFA lesion demonstrate some QoL benefits, but at 12 months post PTA do not approach 
the QoL scores of an age-matched population. Umlateral claudicants undergoing zliac PTA above a diseased SFA 
demonstrate minzmal QoL changes. 
Conclusions: these results should influence dectszon makzng zn the management of claudicatlon and it may be possible 
to prwrztzse PTA waiting hst~ to ensure patzents wtth greatest potential benefit are treated with most urgency. 
Key Words: Interm#tent claudzcatzon; Percutaneous translummal ngmplasty; Quahty of life. 
Introduction Materials and Methods 
Intermittent claudication is a relatively benign but This study was approved by the ethical committee of 
common problem which has been demonstrated to St. James's and Seacroft University Hospitals. In the 18- 
seriously impair quality of life (QoL). >3 Over recent month period between September 1994 and February 
years there has been a dramatic increase in the use of 1996, all patients undergoing PTA for claudication 
percutaneous transluminal ngioplasty (PTA) in the consented to participate in the study. Patients were 
management of claudication. 4'5This has been based on assessed in the Vascular Laboratory prior to treatment 
the solid foundations of good technical success rates, and at 1, 3, 6 and 12 months post-treatment. 
low complication rates and acceptable patency rates. 6-s 
However, greater proof of efficacy for the procedure 
has been requested 9'1° as the current evidence regarding 
QoL following PTA for claudication is equivocal, n-13 
This study aims to assess the impact of PTA on the Climcal assessment 
QoL of claudicants in the early and medium follow- 
up periods and to identify which patient and arterial Prior to PTA a history was taken using a proforma 
lesion subgroups derive the most benefit from PTA. specifically designed to assess patient reported max- 
imum walking distance (PRWD) on the flat under 
normal conditions, duration of symptoms, affected 
* Please address all correspondence to I C. Chetter, Department 
of Vascular and Endovascular Surgery, Lmcohl Wing, St James's limb(s), and factors predisposing to peripheral vas- 
Universlty Hospital, Beckett Street, Leeds, LS9 7TF, U K cular disease in accordance with ISCVS suggested 
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reporting standards. 15 A physical examination was measures five dimensions of health each on three 
then performed including the measurement of right levels: mobihty; self care; usual activities; pam/dis- 
brachial and right and left ankle systolic pressures comfort and anxiety/depression. Thus the EQ gen- 
using a Doppler probe and sphygmomanometer. From erates 243 theoretically possible health states, from 
these measurements resting right and left ankle bra- which a global QoL index can be derived using a 
chial pressure indices (ABPI-R) were calculated. A matrix generated from time trade off (TTO) data. R2 
standardised treadmill test was performed (2.5 km/h  This TTO index is scored from 1 (the best possible 
at 10 ° incline) measuring the time to cessation of health state) to-0.594(theworstpossiblehealthstate). 
walking due to claudication, up to 5 rain. This time The EQ also incorporates a visual analogue scale (VAS) 
was then converted to a maximum treadmill walking on which patients are requested to rate their health 
distance (MTWD). Immediately following treadmill on a scale 0 (worst imaginable health) to 100 (best 
testing, right and left ABPIs were reassessed (ABPI- imaginable health). Thus the EQ produces a QoL 
PE). PRWD, right and left ABPI-R and ABPI-PE, and profile and two global indices of QoL, one derived 
MTWD were all reassessed at 1, 3, 6 and 12 months from a VAS, the other from TTO data. The EQ has 
following PTA. A duplex scan was performed to assess been found to be acceptable, valid and reliable m 
the patency of the angioplastied segment if there was population studies, other patient groups, and in 
no improvement in ABPI-R (i.e. a change of >0.1) at patients with claudication. R°'23'24 However, the re- 
any follow-up appointment, sponslveness of the EQ derived health profile has been 
shown to be poor in claudicants, and thus in this study 
only the EQ derived TTO and VAS derived single 
indices of health were used. R° 
QoL assessment SF36 and EQ questionnaires were sent by post with 
the patient's vascular laboratory appointment letter 
QoL was assessed using the Medical Outcomes Study and a request o complete the questionnaires them- 
Short Form 36 (SF36) and EuroQol (EQ) health status selves at a quiet time of the day, taking time to answer 
questionnaires, honestly. Appointment letters were sent 1-2 weeks 
The SF36, developed from the Medical Outcomes prior to the appointment date. On arrival at the vas- 
Study General Health Survey Instrument, is a stand- cular laboratory, questionnaires were examined and 
ardised generic questionnaire designed for interview patients were prompted to complete any omissions. 
or self completion. It contains 36 questions covering Patients attending without questionnaires were sup- 
eight health domains: physical functioning (PF), role plied with further copies for completion i the vascular 
limitation due to physical problems (RP), social func- laboratory. Thus, fully completed questionnaires were 
tioning (SF), role limitations due to emotional problems presented by all attending patients to the researcher 
(RE), mental health (MH), vitality (Vit), bodily pain performing the assessment (ICC), rather than to the 
(BP), and general health (GH). For each dimension, surgeons directly responsible for the patients' care. 
question scores are coded, summed and transformed 
onto a scale from 0 (worst possible score) to 100 (best 
possible score). In this study the anglicised or U.K. 
version of the SF36 was used. The attraction of the Data analysis 
SF36 is that it is the product of a vast amount of 
developmental work and psychometric testing in the Data was collected usmg a specifically designed Mi- 
U.S.A.  16'17 It is short and covers a wide range of areas crosoft Access database and analysed on a Microsoft 
which may be affected by illness. Response rates have Excel spreadsheet (Microsoft Ltd., Wharfdale Road, 
been shown to be high and British population orms Winnerish Triangle, Wokingham, Berks, U.K.) using 
are available. TM It has been shown to be valid and Astute statistical software (DDU software, The Uni- 
reliable in both population samples and in this specific versity of Leeds, Old Medical School, Leeds, U.K.). 
group of patients. 19'R° It is also more sensitive to change The climcal indicators of lower limb ischaemia re 
in this group of patients than other commonly utilised presented as median values. QoL results are presented 
generic instruments. R° It produces a profile of health as effect sizes, calculated by dividing the difference 
related quality of hfe but unfortunately nosingle index, between the pre-treatment and post-treatment median 
The EQ, developed by a multi-disciplinary group values by the interquartile range of the pre-treatment 
of European researchers, i  also a standardised generic values. Effect sizes have been strongly recommended 
questionnaire designed for interview or self-corn- for interpretation of QoL changes in health care in 
pletion in conjunction with other instruments. 2~ It order to demonstrate the relative importance of a 
Eur J Vase Endovasc Surg Vol 16, December 1998 
Quality of Life Following PTA for Claudication 479 
treatment effect within a study. 25 Kruskal-Wallis Ana- QoL results 
lysis of variance test was used to assess the significance 
of change over time. SF36 scores prior to and at Intermittent claudication causes severe QoL lim- 
12 months following PTA are presented as standard itations, with standard scores in virtually all QoL 
scores, calculated by dividing the differences between domains being _< -0.5. Pre-intervention QoL seems 
the median scores of each subgroup and those of the particularly impaired in patients with multi-segment 
general population by the interquartile range of the disease (i.e. bilateral claudicants and unilateral clau- 
general population. 26Standard scores have been re- dicants undergoing iliac PTA above a diseased SFA) 
commended to facilitate simple comparisons between whose standard scores are in general lower than those 
patient groups and the general population across the patients with single segment disease (Fig. 1). 
entire SF36 profile. 27 
All patients 
Results QoL analysis following PTA in all 117 patients (Fig. 2) 
reveals an immediate and prolonged improvement in 
One hundred and seventeen patients undergoing PTA both global QoL, as indicated by the EQ VAS and TTO 
for claudication were studied, 78 men and 39 women, indices, and the individual SF36 domains of physical 
with a median age 67 years, range 40-87 years. Thirty- functioning, physical role, bodily pain, vitality and 
five patients, 23 men and 12 women, median age 68 social functioning. However, many of these domains 
years (range 42-84 years) reported bilateral symptoms demonstrate a downward trend with effect sizes falling 
and had angiographic evidence of bilateral disease, below 0.5 at 6 and 12 months. PTA has no significant 
These patients underwent PTA to the most syrup- impact on the psychological domains of Role Erno- 
tomatic limb. Eighty-two patients, 56 men and 28 tional or Mental Health in the group as a whole or in 
women, median age 67 years (range 40-87 years) any PTA subgroup, suggesting PTA has a negligible 
reported unilateral symptoms. Of these unilateral clau- placebo effect. The largely negative ffect size of the 
dicants, 19 underwent PTA of an iliac lesion above a SF36 domain general health perception following PTA, 
significantly (>70%) stenosed or occluded superficial despite obvious improvements in global QoL and the 
femoral artery (SFA), 24 underwent PTA of a solitary majority of SF36 domains, detracts from the validity 
iliac lesion and 39 of a solitary SFA lesion. Of the 117 of this specific domain. 
patients, 16 (14%) were diabetic, 43 (37%) were being 
treated for hypertension, 68 (58%) were current 
smokers, 35 (30%) gave a history of ischaemic heart 
disease, 15 (13%) of cerebrovascular disease, 23 (20%) Subgroup analyszs 
of chronic obstructive pulmonary disease, and 23 (20%) 
of hyperlipidaemia. Bilateral claudicants undergoing unilateral PTA deta- 
In eleven (9%) cases the PTA was technically un- onstrate immediate and sustained significant ira- 
successful due to inability to cross the lesion with the provements in global TTO QoL, physical functioning, 
guide wire. Cumulative patency rates for all PTA bodily pain, vitality and social functioning (Fig. 3). 
sites were 83% 78% and 71% at 3, 6 and 12 months, However, despite these improvements, 12months fol- 
respectively, lowing PTA, bilateral claudicants demonstrate per- 
smtent QoL impairments compared to an age-matched 
population (Fig. 1). Umlateral claudicants undergoing 
iliac PTA above a diseased SFA demonstrate minimal 
QoL benefits, with improvement only seen in the SF36 
Climcal outcome in&cators (Table 1) domain social functioning (Fig. 4). With the exception 
of this domain, standard scores at 12 months post- 
Significant improvement in PRWD, ABPI R and ABPI PTA are similar to pre-intervention scores, both of 
PE in the angioplastied limb, and in MTWD were which are substantially lower than those of an age- 
observed in the PTA group as a whole, and all PTA matched population (Fig. 1). 
subgroups (p<0.05) except unilateral claudicants Unilateral claudicants undergoing PTA to a solitary 
undergoing lliac PTA above a diseased SFA who failed lliac lesion demonstrate an immediate and sustained 
to demonstrate an improvement in MTWD (p = 0.31). improvement in both EQ global QoL indices and in 
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All patients Bilateral claudlcants UC UC UC 
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Fig. 1. Standard scores prior to and at 12 months following PTA (ll) 12 months post PTA; ([~) prior to PTA UC =Umlateral clau&cant, 
SF = social functlomng, PF = physical functioning, RP = role physical, BP = boddy pare, Vlt =~ vitahty 
21 
1.5  - -  
*6 
0.5 
-05  
VAS* TTO* PF* RP** BP* GH Vit* SF* RE MH 
Quality of life domain 
Fig. 2. Quahty of hfe changes following PTA all pataents (11) One month, (D) 3 months, (~) 6 months, (m) 12 months VAS=EuroQol 
vmual analogue scale, TTO = EuroQol time trade off mdex, PF = physical functioning, RP = role physmal, BP = bodily pam, GH = general 
health, Vlt= vltahty, SF = social functlomng, RE = role emotional, MH = mental health 
* =p<O.O1, 
** =p<0.05 Kruskal-Walhs analysis of variance 
the majority of SF36 QoL domains (Fig. 5). This is the surprising; however, closer inspection reveals that the 
only subgroup whose QoL 12 months following PTA majority of the other domains do demonstrate a tend- 
approaches that of a age-matched population (Fig. 1). ency to improvement, as indicated by the largely 
The only QoL domain to demonstrate significant positive effect sizes, but this fails to reach statistical 
improvement in unilateral claudicants following PTA significance (Fig. 6). However, at 12 months, QoL 
to a solitary SFA lesion is the EQ VAS global QoL scores in these patients do begin to approach those of 
index. This on imtial examination may seem slightly an age-matched population (Fig. 1). 
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Fig. 3. Quality of life changes following PTA bilateral claudicants ( . )  One month, ([3) 3 months, (b~) 6 months, (IN) 12 months. VAS= 
EuroQol visual analogue scale, TTO =EuroQol time trade off index, PF =physical functioning, RP =role physical, BP =bodily pare, GH = 
general health, Vlt =vitality, SF = social hmctionmg, RE = role emotional, MH = mental health. 
* =p<0 01, 
** =p<0 5 Kruskal-Walhs analysis of variance 
2 
1.5  - -  
*8 
0 .5 -  
-0.5 
VAS TTO PF RP BP GH Vit SF** RE MH 
Quahty of life domain 
Fig. 4. Quality of life following PTA umlateral c audlcants (lhac lemon above diseased SFA) (B) One month, (D) 3 months, (%) 6 months, 
(IN) 12 months VAS = EuroQol visual analogue scale, TTO = EuroQol time trade off index, PF =physical funchomng, RP = role physmal, 
BP = bodily pain, GH = general health, Vit= vitality, SF = social functlomng, RE = role emotional, MH = mental health. 
* =p<0.01, 
**= p<0 05 Kruskal-Walhs analysis of variance. 
D iscuss ion  means  that pat ients  must  res ign themselves  to these 
l imitat ions.  If these QoL l imitat ions are unacceptable ,  
Intermit tent  c laudicat ion is essent ia l ly  a ben ign  dis- it has  been suggested  that in all c laudicants  w i th  an 
ease, w i th  the major i ty  of pat ients  remain ing  stable, 28 amenab le  arter ial  lesion, PTA shou ld  be cons idered  
thus a conservat ive approach  to its management  is amongst  he pr imary  t reatment  opt ions2 ° The cl inical 
genera l ly  recommended.  29 However ,  we have dem-  mdmator  outcomes in this s tudy  wou ld  certa in ly 
onst rated here that c laudicat ion causes QoL im- appear  to suppor t  this suggest ion.  The QoL 
pa i rments ,  and conservat ive management  inev i tab ly  outcome indicators  wou ld  also suggest  that all 
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Fig. 5. Quality of hfe changes following PTA. unilateral c audlcants (sohtary lhac lesmn) ( I )  One month, ([]) 3months, (~) • months, 
([]) 12 months VAS = EuroQol visual analogue scale, TTO = EuroQol hme trade off index, PF = physical funchonmg, RP = role physical, 
BP = bodily pam, GH = general health, Vit = vitahty, SF = socml funchonmg, RE = role emohonal, MH = mental health 
* =p<0 1, 
**= p<0 05 Kruskal-Walhs analysm of varmnce 
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Quahty of life dommn 
Fig. 6. Quality of hfe following PTA umlateral c audlcants (sohtary SFA lesion). ( I )  One month, ([B) 3 months, (~) 6 months, ([]) 12 
months. VAS=EuroQol visual analogue scale, TTO=EuroQol hme trade off index, PF=physlcal functioning, RP=role physical, BP= 
bodily pare, GH = general health, Vlt = vltahty, SF = socml funchonmg, RE = role emohonal, MH = mental health 
* =p<0 01, 
** =p<0 5 Kruskal-Walhs analysis of variance 
uni lateral  c laudicants wi th  a sol itary iliac lesion to be expected. Iliac PTA above a signif icantly 
amenable  to PTA should undergo  the procedure as a diseased SFA wou ld  appear to be an inadequate sole 
pr imary  t reatment  option, as PTA in these pat ients t reatment for claudication. Potential  explanat ions for 
results in a return to a "normal"  QoL. Bilateral claudi- residual  QoL hmitat ions fo l lowing PTA in these latter 
cants or uni lateral  c laudicants wi th  a solitary SFA groups of c laudicants inc lude age variat ions, co- 
lesion, can also expect some QoL improvements  morb id  condit ions, and residual  or recurrent  claudi- 
fo l lowing PTA, but  res idual  QoL impa i rments  are cation. 
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Conclusion 13 WHYMAN MR, FOWKES FGR, KERRACHER EMG, GILLESPIE IN, 
LEE AJ, HOUSLEY E, RUCKLEY CV Randomzsed controlled trial 
of percutaneous translulmnal ngloplasty for mterlmttent clau- 
On ly  approx imate ly  10% of c laud icants  w i l l  have  a &cation. Eurl Vasc Endovasc Surg 1996, 12 167-172 
les ion  amenab le  to PTA. 13 The  ev idence  presented  here  14 FLETCHER A, GORE S, JONES D, FITZPATRICK R, SPEIGELHALTER 
D, Cox D Quality of life measures in health care. II. design, 
should assist both doctors and patients in deciding analyms and interpretation. BrMed Journal 1992, 305. 1145-1148. 
whether  PTA is appropr ia te  in the  management  of an  15 AD Hoc COMMITTEE ON REPORTING STANDARDS, SOCIETY FOR 
ind iv idua ls  c laud icat ion ,  thus  ensur ing  jud ic ious  use  VASCULAR SURGERY/NORTH AMERICAN CHAPTERt INTER- 
NATIONAL SOCIETY FOR CARDIOVASCULAR SURGERY Suggested 
of resources .  It may  also be  poss ib le  to pr ior i t i se  PTA standards for reports deahng with lower extremity lschaemla [
wa i t ing  l ists to ensure  pat ients  w i th  greates t  potent ia l  Vasc Surg 1986, 4 80-94 
benefit are treated with most urgency. 16 WARE JE, SHERBOURNE C The MOS 36-item short-form health 
survey 1 conceptual framework and item selection. Med Care 
1992, 30 473-483 
17 McHORNEY CA, WARE JE, RACZEK AE The MOS 36-Rein short- 
form health survey (SF36): II Psychometric and chmca] tests for 
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